Immunotherapy drug delays recurrence in kidney cancer patients (IMAGE)

Dana-Farber Cancer Institute

Immunotherapy drug delays recurrence in kidney cancer patients

Caption

Toni K. Choueiri, MD, Dana-Farber Cancer Institute, led KEYNOTE-564 clinical trial. Interim results show adjuvant immunotherapy in kidney cancer revealed a 32% decrease in the risk of recurrence or death.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly courtesy Dana-Farber Cancer Institute

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.